User: Guest  Login
Document type:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Ohlmann, Carsten-Henning; Jäschke, Michelle; Jaehnig, Peter; Krege, Susanne; Gschwend, Jürgen; Rexer, Heidrun; Junker, Kerstin; Zillmann, Roger; Rüssel, Christoph; Hellmis, Eva; Suttmann, Henrik; Janssen, Martin; Marin, Jan; Hübner, Andreas; Mathers, Michael; Gleißner, Jochen; Scheffler, Michael; Feyerabend, Susan; Telle, Jens; Klier, Jörg; Stöckle, Michael
Title:
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Abstract:
BACKGROUND: Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary. METHODS: In this exploratory phase 2 study, mCRPC patients were rando...     »
Journal title abbreviation:
Prostate Cancer Prostatic Dis
Year:
2022
Journal volume:
25
Journal issue:
4
Pages contribution:
778-784
Fulltext / DOI:
doi:10.1038/s41391-022-00533-6
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35430584
Print-ISSN:
1365-7852
TUM Institution:
Klinik und Poliklinik für Urologie
 BibTeX